Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Gyre Therapeutics Inc (NASDAQ: GYRE) closed the day trading at $8.57 down -30.21% from the previous closing price of $12.28. In other words, the price has decreased by -$30.21 from its previous closing price. On the day, 0.74 million shares were traded. GYRE stock price reached its highest trading level at $11.5 during the session, while it also had its lowest trading level at $8.485.
Ratios:
For a better understanding of GYRE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.29 and its Current Ratio is at 3.72. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On February 10, 2021, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $15.Piper Sandler initiated its Overweight rating on February 10, 2021, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 14 ’25 when Ma Songjiang sold 2,000 shares for $12.31 per share. The transaction valued at 24,620 led to the insider holds 2,831,260 shares of the business.
Ma Songjiang sold 2,000 shares of GYRE for $23,600 on Mar 13 ’25. The President now owns 2,833,260 shares after completing the transaction at $11.80 per share. On Mar 12 ’25, another insider, Ma Songjiang, who serves as the President of the company, sold 2,000 shares for $11.74 each. As a result, the insider received 23,480 and left with 2,835,260 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GYRE now has a Market Capitalization of 1051753216 and an Enterprise Value of 812268608. Its current Enterprise Value per Revenue stands at 7.681 whereas that against EBITDA is 45.59.
Stock Price History:
The Beta on a monthly basis for GYRE is 1.79, which has changed by -0.52015674 over the last 52 weeks, in comparison to a change of 0.07465422 over the same period for the S&P500. Over the past 52 weeks, GYRE has reached a high of $19.00, while it has fallen to a 52-week low of $8.26. The 50-Day Moving Average of the stock is -23.81%, while the 200-Day Moving Average is calculated to be -29.90%.
Shares Statistics:
Over the past 3-months, GYRE traded about 91.57K shares per day on average, while over the past 10 days, GYRE traded about 178580 shares per day. A total of 85.77M shares are outstanding, with a floating share count of 16.16M. Insiders hold about 81.17% of the company’s shares, while institutions hold 2.08% stake in the company. Shares short for GYRE as of 1740700800 were 1346149 with a Short Ratio of 14.70, compared to 1738281600 on 1248253. Therefore, it implies a Short% of Shares Outstanding of 1346149 and a Short% of Float of 20.02.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
For the next quarter, 1 analysts are estimating revenue of $25.2M. There is a high estimate of $25.2M for the next quarter, whereas the lowest estimate is $25.2M.
A total of 1 analysts have provided revenue estimates for GYRE’s current fiscal year. The highest revenue estimate was $135.7M, while the lowest revenue estimate was $135.7M, resulting in an average revenue estimate of $135.7M. In the same quarter a year ago, actual revenue was $105.76MBased on 1 analysts’ estimates, the company’s revenue will be $238M in the next fiscal year. The high estimate is $238M and the low estimate is $238M.
